Contact Us
Drug Search Results
More Filters [+]

Aclarubicin

Alternative Names: aclarubicin, aclacinomycin A, aclacin, aclaplastin
Latest Update: 2024-04-25
Latest Update Note: PubMed Publication

Product Description

An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine.

Mechanisms of Action: TOP Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Germany | India | Pakistan | Taiwan

Approved Indications: None

Known Adverse Events: None

Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aclarubicin

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Acute Myeloid Leukemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CTR20202269

P3

Not yet recruiting

Acute Myeloid Leukemia

None

Recent News Events

Date

Type

Title

04/25/2024

PubMed

 Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study.

01/01/2024

PubMed

 [Acute myeloid leukemia with central nervous system involvement successfully treated with gilteritinib].

10/12/2023

PubMed

 Next-generation sequencing reveals relapse and leukemia-free survival risks in newly diagnosed acute myeloid leukemia treated with CAG regimen combined with decitabine.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions